Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
About Cellectis
Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.
Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs
Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.
Proprietary Technologies
Cellectis’s competitive edge lies in its proprietary technologies:
- TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
- PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.
These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.
Market Position and Industry Context
Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.
Competitive Landscape
Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.
Challenges and Opportunities
While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.
Conclusion
Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs and strategic partnerships. The company maintains a strong cash position of $264 million, providing runway into mid-2027.
Key pipeline updates include:
- UCART22 Phase 1 data and development strategy expected in Q3 2025, with FDA granting Orphan Drug and Rare Pediatric Disease Designations
- UCART20x22 Phase 1 study in NHL ongoing with readout expected late 2025
- Three active programs in collaboration with AstraZeneca
Notable corporate developments include AstraZeneca's $140 million additional equity investment and the completion of European Investment Bank financing drawdown of €40 million. The company has deprioritized UCART123 development to focus on BALLI-01 and NATHALI-01 studies.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing platforms for cell and gene therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after US market close.
The company will host an investor conference call and webcast on March 14, 2025, at 8:00 AM ET / 1:00 PM CET to discuss the financial results and provide business updates. Investors can access the call through domestic (+1-800-225-9448) or international (+1-203-518-9708) dial-in numbers using Conference ID: CLLS24.
Cellectis (CLLS) has released its monthly share capital and voting rights report as required by Article 223-16 of the French financial markets authority's General Regulation. The company's shares are listed on Euronext Growth under ISIN code FR0010425595.
Cellectis (NASDAQ: CLLS) presented its 'Smart CAR T' strategy at AACR-IO 2025, showcasing an innovative approach to enhance CAR T cell efficacy against solid tumors. The presentation focused on a technique using interleukin 2 (IL-2) to improve treatment outcomes.
The company's research demonstrates that their TALEN® gene editing technology enables CAR T cells to express a CAR-inducible IL-2 variant (IL-2v) immunocytokine, which is activated by tumor-specific signals within the solid tumor microenvironment (TME). This engineered IL-2v boosts anti-tumor activity both in vitro and in vivo, while minimizing systemic toxicity by anchoring to the FAP protein present in the TME.
The development aims to improve CAR T-cell expansion and persistence without the toxicity risks typically associated with high-dose IL-2 administration, potentially representing a safer and more effective treatment approach for solid tumors.
Cellectis has released its monthly share capital and voting rights update as of January 31, 2025, in accordance with Article 223-16 of the French financial markets authority's General Regulation. The company reported a total of 100,093,873 shares in capital and 88,660,571 voting rights. This information was disclosed for the Euronext Growth market, where Cellectis trades under the ISIN code FR0010425595.
Cellectis has released its monthly share capital and voting rights report as of December 31, 2024. The company reported a total of 100,093,873 shares in the capital and 88,660,539 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth under ISIN code FR0010425595.
Cellectis (NASDAQ: CLLS) has drawn down the final €5 million tranche (Tranche C) from its €40 million credit facility agreement with the European Investment Bank (EIB). The disbursement is expected by December 18, 2024, completing the full €40 million facility established on December 28, 2022.
The funds will support the development of Cellectis' allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As part of the agreement, Cellectis issued 611,426 warrants to the EIB, each convertible into one ordinary share at €1.70 per share, representing approximately 0.6% of the company's outstanding shares. Tranche C has a six-year maturity with a 6% annual interest rate, capitalized annually and payable at maturity.
Cellectis has released its monthly share capital and voting rights information as of November 30, 2024. The company reported a total of 100,093,873 shares in the capital and 88,576,206 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, with the company's shares listed on Euronext Growth under ISIN code FR0010425595.
Cellectis has reported its monthly share capital and voting rights information as of October 31, 2024. The company disclosed a total of 100,093,873 shares in the capital and 88,569,210 voting rights. This disclosure is made in compliance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth under ISIN code FR0010425595.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis’s proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis’s main competitors?
What stage of development is Cellectis in?
